Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

PRIMARY OBJECTIVES: I. Overall response rate. SECONDARY OBJECTIVES: I. Progression-free survival. II. Median overall survival. III. One-year overall survival. EXPLORATORY OBJECTIVES: I. Tissue and blood correlates to define immune infiltration and signatures as a result of treatment with nivolumab plus ipilimumab. OUTLINE: INDUCTION PHASE: Patients receive nivolumab intravenously (IV) over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 60 days.